drugset / Trial / NCT04104438

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

NCT04104438

Phase 4 Completed 71 enrolled Fady M Kaldas, M.D., F.A.C.S.
RandomizedSequentialOpen-labelTreatment

Summary

This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study will assess how safe the new combination of immunosuppressive medicines are and if there are any changes in how your kidneys work after taking these medicines.

Timeline

Start
2021-01-15
Primary completion
2024-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Basiliximab Monoclonal antibody 20 mg Intravenous
Comparator Everolimus Small molecule 1 mg Oral
Comparator Tacrolimus Small molecule Oral
Comparator mycophenolic acid Small molecule

Indications

No indication recorded.